In patients with advanced melanoma, the vaccine along with immunotherapy reduced the risk of cancer recurrence and death by 44%, the companies said.
. It involved 157 patients with advanced melanoma who had their tumors completely surgically removed. These patients were randomly split into two groups who received treatment for about a year. One group was given regular infusions of Merck’s Keytruda, a lab-made antibody that helps immune cells better recognize and kill certain cancers. The other group was given Keytruda and nine doses in total of the vaccine candidate, called mRNA-4157/V940.
cancer returning on average than those who only received Keytruda . The vaccine in conjunction with Keytruda also appeared to reduce the combined risk of cancer recurrence and death by 44%.“Today’s results are highly encouraging for the field of cancer treatment.
We all need privacy, especially online. Your IP address and your browsing should be hidden from unecessary surveillance. Rest assured that PIA’s virtual private network never keeps any usage logs—ever.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Moderna's mRNA Skin Cancer Vaccine Shows Early Promise in a New StudyThe company reported encouraging results from a small study
Consulte Mais informação »
Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary StudyA customized Moderna vaccine combined with a Merck immunotherapy helped ward off the recurrence of skin cancer in people in a midstage trial
Consulte Mais informação »
Experimental mRNA cancer vaccine with immunotherapy reduces risk of melanoma returning, preliminary study finds | CNNAn experimental personalized mRNA vaccine in combination with the immunotherapy Keytruda reduced the risk of recurrence or death from melanoma in patients who had already had surgery, Moderna and Merck said Tuesday.
Consulte Mais informação »
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Consulte Mais informação »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Consulte Mais informação »
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said.
Consulte Mais informação »